Improving 56 Risk Factors Might Avert 40%-63% of Sudden Cardiac Arrests
Study findings link key risk factors to sudden cardiac arrest, highlighting need for primary prevention.
Related Articles
Probiotics, Prebiotics Tied to Decreased Depression, Anxiety
The use vs nonuse of probiotics and prebiotics, alone or combined, are linked to a greater decrease in depression and anxiety symptoms, new research shows.
Add-On Niraparib May Slow Hormone-Sensitive Metastatic Prostate Cancer
Adding Niraparib to standard therapy slows tumor growth and time to symptomatic progression in men with metastatic hormone sensitive prostate cancer.
Katalin Karikó on mRNA’s Next Frontier: Beyond COVID
The Nobel laureate discusses the future of RNA-based therapies, from cancer to autoimmune disease — and why basic research still matters.
UK Valproate Restrictions in Men Justified? New Data
A new analysis shows no clear link between paternal valproate use and harm in offspring, raising questions about the EMA restrictions in men aged 55…
Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends
Both the incidence and prevalence of syphilitic uveitis increased in the United States from 2013 to 2024, with low vision and blindness being the most…
Breast Cancer, Familial: Primary Care Management
An easy-to-read NICE guidance summary on the classification and care of people at risk of familial breast cancer or with a family history of breast…
Jun 06 2025 This Week in Cardiology
Listener feedback on cardiac sarcoidosis, out-of-hospital cardiac arrest, less is more when it comes to post-stent antiplatelets, lipoprotein(a), and atrial fibrillation in HFpEF are discussed…
GLP-1 Less Frequent Dosing May Maintain Weight Loss
A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists is an effective and cost-saving strategy…
Patient Experience, Adults: NHS Services
This summary covers the components of a good patient experience. It includes recommendations on tailoring healthcare services and continuity of care
Sibeprenlimab Halves uPCR in IgA Nephropathy Trial
The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent safety outcomes, interim phase 3 data shows.